ARTICLE | Clinical News
CXB722: Phase I data
January 18, 2010 8:00 AM UTC
In a Phase I trial in 24 healthy volunteers, CXB722 significantly reduced several neuroendocrine biomarkers that typically rise in response to acute psychosocial stress, including plasma cortisol, sal...